PRL-3 is highly expressed in ~80% of 151 human tumor tissue samples across 11 tumor types, including liver, lung, colon, breast, stomach, thyroid, pancreas, kidney, bladder, and prostate cancer10, and PRL-3 has been extensively reported as a biomarker of tumor progression and metastasis in breast11, colon12,13, gastric14, brain15, and prostate16 cancers. Here, PTP4A3 is linked to neoplasm.